Curing Macular Degeneration
Through Tissue Engineering Innovation
Tissue Engineering Innovations
Solutions To Global Crisis
Macular degeneration is a leading cause of vision loss in Americans 60 years of age and older. As many as 11 million people in the United States have some form of age-related macular degeneration. This number is expected to double to nearly 22 million by 2050. The number of people living with macular degeneration is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040.
Estimates of the global cost of visual impairment due to age-related macular degeneration is $343 billion, including $255 billion in direct health care costs.
MacularDegeneration Crisis
Current treatments cannot cure macular degeneration. Surgery, Eye Injections, Eye Supplements and Gene Therapy can slow the progression, and are often expensive. Gene therapy for example costs $850,000 for both eyes to be treated.
Mesogen Will Solve This Crisis
- Patients
- Physicians
A Cure Is On The Horizon
Mesogen is actively advancing RPE cell patches for transplant. Contact us to be notified when clinical trials and research partners are announced.
A Curative Solution Is Coming
Contact us today to learn more about our RPE cell patches, and the benefits for your patients. No long-term anti-rejection drugs, less complications and grown from your patients own cells.
How it Works
Bone Marrow Aspiration
Stem Cell Isolation
Stem Cell Expansion
Stem Cell Differentiation to RPE Cells
Completed RPE Patch
RPE Patch Transplant
A Cure Is Coming
Take The First Step Towards Your Future
Take control of your future and get in touch with us today to explore how Mesogen can assist you. Whether you’re a physician or a patient, we’re actively engaged in different stages of development and would love to discuss how we can support your goals. Don’t hesitate, reach out today!
